11 Korean-developed medicines break the U.S. and EU wall of approval
11 medicines which were developed by Korean pharmaceutical companies after 2013 have reportedly been well sold as breaking the wall of approval of the U.S. and European Union.
According to the Ministry of Health and Welfare, starting with Celltrion’s Remsima which acquired approval from the Euro...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
